103 related articles for article (PubMed ID: 38735639)
1. Radio theranostics in paragangliomas and pheochromocytomas.
Prado Wohlwend S; Bello Arques P;
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2024 May; ():500017. PubMed ID: 38735639
[TBL] [Abstract][Full Text] [Related]
2. [
Prado-Wohlwend S; Del Olmo-García MI; Bello-Arques P; Merino-Torres JF
Front Endocrinol (Lausanne); 2022; 13():778322. PubMed ID: 35197929
[TBL] [Abstract][Full Text] [Related]
3. Response to targeted radionuclide therapy with [
Prado-Wohlwend S; Del Olmo-García MI; Bello-Arques P; Merino-Torres JF
Front Endocrinol (Lausanne); 2022; 13():957172. PubMed ID: 36339441
[TBL] [Abstract][Full Text] [Related]
4. Role of imaging test with radionuclides in the diagnosis and treatment of pheochromocytomas and paragangliomas.
Araujo-Castro M; Pascual-Corrales E; Alonso-Gordoa T; Molina-Cerrillo J; Martínez Lorca A
Endocrinol Diabetes Nutr (Engl Ed); 2022 Oct; 69(8):614-628. PubMed ID: 36402734
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of [
Hertelendi M; Belguenani O; Cherfi A; Folitar I; Kollar G; Polack BD
Biomedicines; 2023 Mar; 11(4):. PubMed ID: 37189646
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology of Neuroendocrine Neoplasms and Results of Their Treatment with [
Durma AD; Saracyn M; Kołodziej M; Jóźwik-Plebanek K; Dmochowska B; Kapusta W; Żmudzki W; Mróz A; Kos-Kudła B; Kamiński G
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001726
[TBL] [Abstract][Full Text] [Related]
7. Peptide receptor radionuclide therapy with [
Prado-Wohlwend S; Bernal-Vergara JC; Utrera-Costero A; Cañón-Sánchez JR; Agudelo-Cifuentes M; Bello-Arques P;
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2022; 41(1):55-65. PubMed ID: 34920969
[TBL] [Abstract][Full Text] [Related]
8. Systemic Radiopharmaceutical Therapy of Pheochromocytoma and Paraganglioma.
Carrasquillo JA; Chen CC; Jha A; Pacak K; Pryma DA; Lin FI
J Nucl Med; 2021 Sep; 62(9):1192-1199. PubMed ID: 34475242
[TBL] [Abstract][Full Text] [Related]
9. Quantitative analysis of
Ma G; Du J; Zhang X; Liu J; Xu X; Xu B; Guan Z
Quant Imaging Med Surg; 2022 Apr; 12(4):2427-2440. PubMed ID: 35371938
[TBL] [Abstract][Full Text] [Related]
10. Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups.
Taïeb D; Jha A; Treglia G; Pacak K
Endocr Relat Cancer; 2019 Nov; 26(11):R627-R652. PubMed ID: 31561209
[TBL] [Abstract][Full Text] [Related]
11. Management and outcome of metastatic pheochromocytomas/paragangliomas: an overview.
De Filpo G; Maggi M; Mannelli M; Canu L
J Endocrinol Invest; 2021 Jan; 44(1):15-25. PubMed ID: 32602077
[TBL] [Abstract][Full Text] [Related]
12. Peptide receptor radionuclide therapy with 177Lu- or 90Y-SSTR peptides in malignant pheochromocytomas (PCCs) and paragangliomas (PGLs): results from a single institutional retrospective analysis.
Rubino M; Di Stasio GD; Bodei L; Papi S; Rocca PA; Ferrari ME; Fodor CI; Bagnardi V; Frassoni S; Mei R; Fazio N; Ceci F; Grana CM
Endocrine; 2024 May; 84(2):704-710. PubMed ID: 38324106
[TBL] [Abstract][Full Text] [Related]
13. Radioligand Therapy with [
Durma AD; Saracyn M; Kołodziej M; Jóźwik-Plebanek K; Dmochowska B; Mróz A; Żmudzki W; Kamiński G
Pharmaceuticals (Basel); 2023 Aug; 16(9):. PubMed ID: 37765013
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic drugs in somatostatin type 2 receptor radionuclide theranostics and radiation transcriptomics in mouse pheochromocytoma models.
Ullrich M; Richter S; Liers J; Drukewitz S; Friedemann M; Kotzerke J; Ziegler CG; Nölting S; Kopka K; Pietzsch J
Theranostics; 2023; 13(1):278-294. PubMed ID: 36593963
[TBL] [Abstract][Full Text] [Related]
15. Real-world comparison of healthcare resource utilization and costs of [
Cox T; O'Connell M; Leeuwenkamp O; Palimaka S; Reed N
Curr Med Res Opin; 2022 Aug; 38(8):1305-1317. PubMed ID: 35418254
[TBL] [Abstract][Full Text] [Related]
16. Performance of
Han S; Suh CH; Woo S; Kim YJ; Lee JJ
J Nucl Med; 2019 Mar; 60(3):369-376. PubMed ID: 30030341
[TBL] [Abstract][Full Text] [Related]
17. 'Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: A systematic review and meta-analysis'.
Satapathy S; Mittal BR; Bhansali A
Clin Endocrinol (Oxf); 2019 Dec; 91(6):718-727. PubMed ID: 31569282
[TBL] [Abstract][Full Text] [Related]
18. Early short-term effects on catecholamine levels and pituitary function in patients with pheochromocytoma or paraganglioma treated with [
Gubbi S; Al-Jundi M; Auh S; Jha A; Zou J; Shamis I; Meuter L; Knue M; Turkbey B; Lindenberg L; Mena E; Carrasquillo JA; Teng Y; Pacak K; Klubo-Gwiezdzinska J; Del Rivero J; Lin FI
Front Endocrinol (Lausanne); 2023; 14():1275813. PubMed ID: 37886645
[TBL] [Abstract][Full Text] [Related]
19. Metastatic Pheochromocytomas and Abdominal Paragangliomas.
Granberg D; Juhlin CC; Falhammar H
J Clin Endocrinol Metab; 2021 Apr; 106(5):e1937-e1952. PubMed ID: 33462603
[TBL] [Abstract][Full Text] [Related]
20. The Search for an Alternative to [
Waldmann CM; Stuparu AD; van Dam RM; Slavik R
Theranostics; 2019; 9(5):1336-1347. PubMed ID: 30867834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]